

Press Release

March 15, 2007 8:00:00 AM

Epiphany Biosciences Raises \$36 Million Round in Private Financing

Epiphany Biosciences, a new biotech company with a therapeutic focus on discovering and developing anti-infective agents, announced today the closing of a \$36 million Series A financing. Wexford Capital, LLC led the financing and was joined by major investor Windsor Bay Capital, LLC and by Global Trust Ventures Management, LLC, CDIB BioScience Venture Management (CBVM) and several private investors.

“We are extremely pleased to have attracted such a high-quality group of investors,” said Epiphany CEO Fred Volinsky, MD. “Epiphany has assembled one of the finest virology teams in life science today, a group that includes our Chief Scientific Officer Michael Houghton, PhD, Chief Medical officer Brian Murphy, MD, MBA, co-founder Robert Gallo, MD, and Scientific Advisory Board members Drs. Roger Kornberg, Hans Wigzell, Yuan Chang, Patrick Moore, and other eminent scientists and clinicians,” noted Volinsky.

“The funding will enable us to advance our lead programs including our anti-viral drug candidate Valomaciclovir (EPB-348) through Phase 2b clinical trials against shingles as well as Epiphany’s development of HHV-8/KSHV screening diagnostics,” added David Myles, PhD, COO.

Epiphany is committed to bringing life-improving therapeutics and diagnostics to patients suffering from chronic and debilitating conditions caused by infectious agents.

About Epiphany Biosciences

About Epiphany Biosciences

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella zoster virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).